0000899243-17-027391.txt : 20171124 0000899243-17-027391.hdr.sgml : 20171124 20171124163305 ACCESSION NUMBER: 0000899243-17-027391 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20171121 FILED AS OF DATE: 20171124 DATE AS OF CHANGE: 20171124 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SHANGHVI DILIP S CENTRAL INDEX KEY: 0001249644 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38293 FILM NUMBER: 171221618 MAIL ADDRESS: STREET 1: 17/B, MAHALINDUSTRIAL ESTATE STREET 2: MAHAKI CAVES ROAD CITY: ANDEHERI (EAST) STATE: K7 ZIP: 400 093 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sun Pharmaceutical Industries, Inc. CENTRAL INDEX KEY: 0001721949 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38293 FILM NUMBER: 171221616 BUSINESS ADDRESS: STREET 1: C/O SCPHARMACEUTICALS, INC. STREET 2: 2400 DISTRICT AVE., SUITE 310 CITY: BURLINGTON STATE: MA ZIP: 01830 BUSINESS PHONE: 617-517-0730 MAIL ADDRESS: STREET 1: C/O SCPHARMACEUTICALS, INC. STREET 2: 2400 DISTRICT AVE., SUITE 310 CITY: BURLINGTON STATE: MA ZIP: 01830 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SUN PHARMACEUTICAL INDUSTRIES LTD CENTRAL INDEX KEY: 0001197089 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38293 FILM NUMBER: 171221619 BUSINESS ADDRESS: STREET 1: 17/B, MAHAL INDUSTRIAL ESTATE STREET 2: MAHAKALI CAVES ROAD CITY: ANDEHERI (EAST) STATE: K7 ZIP: 400 093 BUSINESS PHONE: 01191228212128 MAIL ADDRESS: STREET 1: 17/B, MAHAL INDUSTRIAL ESTATE STREET 2: MAHAKALI CAVES ROAD CITY: ANDEHERI (EAST) STATE: K7 ZIP: 400 093 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sun Pharma (Netherlands) B.V. CENTRAL INDEX KEY: 0001717322 STATE OF INCORPORATION: P7 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38293 FILM NUMBER: 171221617 BUSINESS ADDRESS: STREET 1: POLARISAVENUE 87 CITY: 2132 JH HOOFDDORP STATE: P7 ZIP: 00000 BUSINESS PHONE: (609) 819-8200 MAIL ADDRESS: STREET 1: POLARISAVENUE 87 CITY: 2132 JH HOOFDDORP STATE: P7 ZIP: 00000 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: scPharmaceuticals Inc. CENTRAL INDEX KEY: 0001604950 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 465184075 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2400 DISTRICT AVENUE STREET 2: SUITE 310 CITY: BURLINGTON STATE: MA ZIP: 01830 BUSINESS PHONE: 617-517-0730 MAIL ADDRESS: STREET 1: 2400 DISTRICT AVENUE STREET 2: SUITE 310 CITY: BURLINGTON STATE: MA ZIP: 01830 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-11-21 0 0001604950 scPharmaceuticals Inc. SCPH 0001197089 SUN PHARMACEUTICAL INDUSTRIES LTD SUN HOUSE, 201 B/1, WESTERN EXPRESS HIGHWAY, GOREGAON (E) MUMBAI MAHARASHTRA K7 400063 INDIA 0 0 1 0 0001249644 SHANGHVI DILIP S SUN HOUSE, 201 B/1, WESTERN EXPRESS HIGHWAY, GOREGAON (E) MUMBAI MAHARASHTRA K7 400063 INDIA 0 0 1 0 0001717322 Sun Pharma (Netherlands) B.V. POLARISAVENUE 87 HOOFDDORP P7 2132 JH NETHERLANDS 0 0 1 0 0001721949 Sun Pharmaceutical Industries, Inc. 270 PROSPECT PLAINS ROAD CRANBURY NJ 08512 0 0 1 0 Common Stock 2017-11-21 4 C 0 1810536 A 1810536 I By Sun Pharmaceutical Industries, Inc. Common Stock 2017-11-21 4 P 0 357143 14.00 A 357143 I By Sun Pharma (Netherlands) B.V. Series B Preferred Stock 2017-11-21 4 C 0 13000000 0.00 D Common Stock 1810536 0 I By Sun Pharmaceutical Industries, Inc. Represents the total number of shares of Common Stock received by Sun Pharmaceutical Industries, Inc. upon conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering. Sun Pharmaceutical Industries Limited ("Sun Pharma") directly and indirectly owns all shares of Sun Pharmaceutical Industries, Inc., which is the registered owner of the securities. Sun Pharma may be deemed to beneficially own all of the shares of the Issuer held by Sun Pharmaceutical Industries, Inc. Dilip S. Shanghvi is the controlling shareholder of Sun Pharma. Sun Pharma and Mr. Shanghvi disclaim beneficial ownership of the reported shares except to the extent of their respective pecuniary interests therein. Sun Pharma is the sole shareholder of Sun Pharma (Netherlands) B.V., which is the registered owner of the securities. Sun Pharma may be deemed to beneficially own all of the shares of the Issuer held by Sun Pharma (Netherlands) B.V. Dilip S. Shanghvi is the controlling shareholder of Sun Pharma. Sun Pharma and Mr. Shanghvi disclaim beneficial ownership of the reported shares except to the extent of their respective pecuniary interests therein. All series of the Issuer's Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis on November 21, 2017. The Series B Preferred Stock had no expiration date. Exhibit 24 - Power of Attorney /s/ Dilip S. Shanghvi 2017-11-24 /s/ Jeremy Barr, Attorney-in-Fact (on behalf of Sun Pharmaceutical Industries Limited) 2017-11-24 /s/ Jeremy Barr, Attorney-in-Fact (on behalf of Sun Pharmaceutical Industries, Inc.) 2017-11-24 /s/ Jeremy Barr, Attorney-in-Fact (on behalf of Sun Pharma (Netherlands) B.V.) 2017-11-24 EX-24 2 attachment1.htm EX-24 DOCUMENT
                               POWER OF ATTORNEY

     Know all by these presents, that the undersigned hereby constitutes and
appoints each of Jeremy Barr and Evgeniya Berezkina, and with full power of
substitution, as the undersigned's true and lawful attorney-in-fact to:

     (1)   execute for and on behalf of the undersigned, in connection with the
undersigned's beneficial ownership of, or participation in a group with respect
to, securities beneficially owned, directly or indirectly, of scPharmaceuticals
Inc., a Delaware corporation (the "Company"), forms and documents related
specifically to Section 13 and Section 16 of the Securities Exchange Act of 1934
and the rules thereunder (the "Exchange Act"), and any joint filing agreement in
connection with the foregoing;

     (2)   do and perform any and all acts for and on behalf of the undersigned
which may be necessary or desirable to complete and execute any such forms and
documents related specifically to Section 13 and Section 16 of the Exchange Act,
complete and execute any amendment or amendments thereto, and timely file such
form and documents with the U.S. Securities and Exchange Commission (the "SEC")
and any stock exchange or similar authority; and

     (3)   take any other lawful action of any type whatsoever in connection
with the foregoing which, in the opinion of any such attorney-in-fact, may be of
benefit to, in the best interest of, or legally required by, the undersigned, it
being understood that the documents executed by any such attorney-in-fact on
behalf of the undersigned pursuant to this Power of Attorney shall be in such
form and shall contain such terms and conditions as such attorney-in- fact may
approve in any such attorney-in-fact's discretion.

     The undersigned hereby grants to each such attorney-in-fact with full power
of substitution or revocation, hereby ratifying and confirming all that each
such attorney-in-fact, or each such attorney-in-fact's substitute or
substitutes, shall lawfully do or cause to be done by virtue of this power of
attorney and the rights and powers herein granted.  All lawful acts done by the
attorney-in-fact in this regard shall be deemed to have been done by the
undersigned. The undersigned acknowledges that the foregoing attorneys-in-fact,
in serving in such capacity at the request of the undersigned, are not assuming,
nor is the Company assuming, any of the undersigned's responsibilities to comply
with Section 13 or Section 16 of the Exchange Act.

     This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file forms and documents related
specifically to Section 13 and Section 16 of the Exchange Act with respect to
the undersigned's holdings of and transactions in securities issued by the
Company, or for a period of one (1) year, unless earlier revoked by the
undersigned in a signed writing delivered to each of the foregoing attorneys-in-
fact, whichever is earlier.


     IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 24th day of November, 2017.


                                   Sun Pharmaceutical Industries Ltd.

                                   By: /s/ Sailesh T. Desai
                                       -----------------------------
                                       Name: Sailesh T. Desai
                                       Title: Director

                                   Sun Pharmaceutical Industries, Inc.

                                   By: /s/ Abhay Gandhi
                                       -----------------------------
                                       Name: Abhay Gandhi
                                       Title: CEO - North America

                                   Sun Pharma (Netherlands) B.V.


                                   By: /s/ Prashant Salva
                                       -----------------------------
                                       Name: Prashant Salva
                                       Title: Director